TIROSINT-SOL Drug Patent Profile

Which patents cover Tirosint-sol, and when can generic versions of Tirosint-sol launch?

Tirosint-sol is a drug marketed by Ibsa and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twenty-five patent family members in thirteen countries.

The generic ingredient in TIROSINT-SOL is levothyroxine sodium. There are ten drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the levothyroxine sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tirosint-sol

A generic version of TIROSINT-SOL was approved as levothyroxine sodium by MYLAN on June 5^th, 2002.

Summary for TIROSINT-SOL

International Patents:	25
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	73
Clinical Trials:	7
Patent Applications:	2,521
Drug Prices:	Drug price information for TIROSINT-SOL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TIROSINT-SOL
DailyMed Link:	TIROSINT-SOL at DailyMed

See drug prices for TIROSINT-SOL

Recent Clinical Trials for TIROSINT-SOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cromsource	Phase 4
University of California, Los Angeles	Phase 4
Children's Mercy Hospital Kansas City	Phase 4

See all TIROSINT-SOL clinical trials

Pharmacology for TIROSINT-SOL

Drug Class

l-Thyroxine

Paragraph IV (Patent) Challenges for TIROSINT-SOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TIROSINT-SOL	Oral Solution	levothyroxine sodium	13 mcg/mL 25 mcg/mL 50 mcg/mL 75 mcg/mL 88 mcg/mL 100 mcg/mL 112 mcg/mL 125 mcg/mL 137 mcg/mL 150 mcg/mL 175 mcg/mL 200 mcg/mL	206977	1	2022-09-30

US Patents and Regulatory Information for TIROSINT-SOL

TIROSINT-SOL is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-008	Dec 15, 2016		RX	Yes	No
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-005	Dec 15, 2016		RX	Yes	No			Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-010	Dec 15, 2016		RX	Yes	No
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-012	Dec 15, 2016		RX	Yes	Yes			Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-009	Dec 15, 2016		RX	Yes	No
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-011	Dec 15, 2016		RX	Yes	No			Y
Ibsa	TIROSINT-SOL	levothyroxine sodium	SOLUTION;ORAL	206977-004	Dec 15, 2016		RX	Yes	No			Y

International Patents for TIROSINT-SOL

See the table below for patents covering TIROSINT-SOL around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	3930703
Spain	2973354
Canada	3129627
Spain	2824787
European Patent Office	3930703
China	113645966
Canada	3037808

Market Dynamics and Financial Trajectory for TIROSINT-SOL: An Industry Analysis

Last updated: January 4, 2026

Summary

TIROSINT-SOL, the synthetic levothyroxine sodium oral solution branded as Tirosint-SOL, is a prescription medication used in treating hypothyroidism. Its unique formulation as an oral liquid offers advantages over traditional tablet formulations, such as improved absorption and dosing flexibility. This analysis explores the current market landscape, key drivers influencing demand, competitive positioning, regulatory environment, and financial outlook. Additionally, it discusses growth prospects propelled by demographic trends, technological innovations, and payer dynamics.

---

What Is the Current Market Environment for TIROSINT-SOL?

Market Overview and Product Profile

Attribute	Details
Generic Name	Levothyroxine sodium (liquid formulation)
Brand Name	Tirosint-SOL
Therapeutic Use	Hypothyroidism, thyroid hormone replacement
Formulation	Oral liquid solution (single-dose vial)
Approval Date (FDA)	March 2019
Market Status	Patented (by IBSA), specialty drug segment

Note: As a liquid formulation, Tirosint-SOL stands out in the hypothyroidism market, traditionally dominated by tablet-based levothyroxine.

Market Size & Revenue

Region	Estimated Global Market (2022)	CAGR (2018-2022)	Key Drivers
North America	USD 770 million	4.8%	Increasing hypothyroidism prevalence, preference for liquid formulations among certain patient groups
Europe	USD 250 million	4.2%	Growing diagnosis rates, aging population
Rest of World	USD 90 million	3.9%	Developing healthcare infrastructure

Total Global Hypothyroidism Drug Market (~ USD 1.11 billion)

---

What Are the Key Market Drivers for TIROSINT-SOL?

Increasing Prevalence of Hypothyroidism

• Estimated at 4-5% of the population worldwide suffers from hypothyroidism, with higher incidence among women aged 50+.
• North America: 12 million individuals, projected to grow with aging demographics (CDC, 2021).

Advantages of Liquid Formulation

• Enhanced Absorption: Greater bioavailability in patients with gastrointestinal issues or absorption impairments.
• Dosing Flexibility: Useful for pediatric, geriatric, or patients requiring titrated doses.
• Reduced Pill Burden: Particularly appealing for patients on polypharmacy regimens.

Regulatory Incentives and Reimbursement Policies

• Favorable national reimbursement schemes for specialty drugs.
• FDA approval in 2019 provided a protected marketing window.
• CMS inclusion under Medicare Part D for certain formulations.

Physician and Patient Preferences

• Growing preference for formulations offering rapid symptom control.
• Increased adoption among endocrinologists and general practitioners.

Demographic Trends

• Rising incidence among aging populations.
• Increased focus on personalized medicine and smaller dosage adjustments.

---

How Does Competitive Positioning Influence Market Share?

Key Competitors

Product	Type	Manufacturer	Market Share (2022)	Unique Features
Synthroid	Tablet	AbbVie	58%	Established brand, extensive formulary coverage
Euthyrox	Tablet	Merck	18%	Widely used in Europe, lower cost
Levoxyl	Tablet	Purdue	12%	Generic availability
Tirosint-SOL	Liquid	IBSA	4%	Liquid formulation, fewer excipients
Other	Generics	Multiple	10%	Competitive pricing

Market Positioning of Tirosint-SOL

• Niche but growing segment within hypothyroidism treatments.
• Positioned as a premium product targeting specific patient segments.
• Incremental market penetration through endocrinologists and specialty clinics.

Barriers to Market Growth

• High cost relative to generic tablets.
• Limited awareness outside specialty physician circles.
• Payer restrictions on coverage for specialty formulations.

---

What Are the Regulatory and Policy Factors Affecting Tirosint-SOL?

Regulatory Milestones

• FDA approval in March 2019.
• Market exclusivity granted until March 2029.

Reimbursement Landscape

• Reimbursed under specialty pharmacy programs.
• Payer coverage varies; some exclude Tirosint-SOL from formularies favoring generics.

Policy Trends Impacting Future Marketability

• Increased emphasis on personalized medicine.
• Potential for expanding indications (e.g., subclinical hypothyroidism management).
• Implementation of stricter cost-effectiveness evaluations by payers.

What Is the Financial Trajectory of Tirosint-SOL?

Revenue Forecasts (2023–2028)

Year	Estimated Revenue (USD million)	Growth Rate	Assumptions
2023	125	—	Launch period stabilization
2024	145	16%	Increased prescribing, expanding awareness
2025	165	14%	Broader clinician acceptance
2026	185	12%	Payer coverage improvement
2027	210	13.5%	Entry into emerging markets
2028	235	11.9%	Possible line extensions

(Source: Industry estimates; market analyst projections)

Revenue Drivers

• Increased diagnosis and treatment rates.
• Adoption among pediatric and geriatric populations.
• Expansion into European and Asian markets.
• Influence of payer policies favoring novel formulations.

Risks and Challenges

• Price sensitivity in developed markets.
• Patent litigation or generic entry after exclusivity lapses.
• Competitive innovations, like transdermal or implantable systems.

---

What Are the Future Growth Opportunities and Challenges?

Opportunities

• Expansion into Emerging Markets: Growing healthcare infrastructure and rising disease awareness.
• Line Extensions: Developing different strengths, combination therapies, or different delivery formats.
• Partnerships & Collaborations: Working with payers for coverage expansion.
• Digital Health Integration: Supporting adherence via mobile apps or digital tracking.

Challenges

• Pricing and Cost Pressure: Payers’ push for cheaper generic alternatives.
• Limited Awareness: Need for targeted clinician education.
• Regulatory Barriers: Delays or restrictions impacting market access.

---

Comparative Analysis: Liquid Versus Tablet Levothyroxine

Attribute	Tirosint-SOL	Traditional Tablets (e.g., Synthroid)
Bioavailability	Superior	Standard
Dosing Flexibility	High	Moderate
Storage & Handling	Reqd. refrigeration	Stable at room temperature
Cost	Higher	Lower
Patient Preference	Favorable (liquid)	Usually tablets

---

FAQs

1. How does Tirosint-SOL compare to traditional levothyroxine tablets regarding efficacy?

Tirosint-SOL offers comparable clinical efficacy to tablets, with evidence suggesting improved absorption in patients with gastrointestinal issues. Pharmacokinetic profiles demonstrate predictable levels, but cost and patient preference influence choice.

2. What are the primary barriers preventing wider adoption of Tirosint-SOL?

High formulation costs, limited clinician awareness, payer restrictions, and competition from cheaper generic tablets impede wider adoption.

3. Are there any upcoming regulatory or patent developments affecting Tirosint-SOL?

IBSA’s patent protection extends until 2029. Future regulatory pathways include potential line extensions or biosimilars following patent expiry, which could impact market share dynamics.

4. How do reimbursement policies influence sales projections?

Reimbursement decisions directly affect patient access. Favorable coverage accelerates uptake; restrictive policies can hinder growth, especially in cost-sensitive markets.

5. What role will technological innovations play in Tirosint-SOL’s future?

Digital adherence tools and delivery innovations could enhance patient outcomes and loyalty, facilitating market expansion and higher lifetime value.

---

Key Takeaways

• Market positioning: Tirosint-SOL occupies a niche in the hypothyroidism treatment landscape, emphasizing absorption benefits and dosing flexibility, appealing to a specific patient subset.
• Growth prospects: Projected compound annual growth rate of approximately 12-15% over the next five years driven by demographic trends and increasing awareness.
• Competitive landscape: While dominant in the generic tablet sector, liquid formulation specialists like Tirosint-SOL are cultivating incremental market share through clinical benefits and niche marketing.
• Regulatory and payer dynamics: Patent protections and reimbursement policies influence revenue streams heavily; strategic engagement with payers can optimize access.
• Risks: Price sensitivity, patent expiry, and healthcare policy shifts pose risks; ongoing innovation and strategic collaborations are essential.

Overall, Tirosint-SOL’s financial trajectory appears promising within a growing but competitive market, provided manufacturers address cost barriers and expand clinician and patient awareness.

---

References

1. CDC. (2021). Hypothyroidism: Fact Sheet. Centers for Disease Control and Prevention.
2. Industry Reports. (2022). Global Hypothyroidism Market Analysis. MarketWatch.
3. FDA. (2019). Approval Letter for Tirosint-SOL.
4. IBSA. (2022). Tirosint-SOL Product Data Sheet.
5. Medicare & Medicaid. (2021). Coverage Policies for Specialty Drugs.

---

Please note, all figures are estimates based on available industry data and analyst projections as of early 2023 and are subject to change with market developments.